BET溴结构域和EZH2抑制剂治疗的慢性GVHD小鼠生发中心钝化且转录组不同
在具有闭塞性细支气管炎的临床相关小鼠cGVHD模型中,EZH2抑制剂JQ5和BET溴结构域抑制剂JQ1各自改善肺功能、削弱生发中心反应;JQ5减少供者T细胞中EZH2介导的H3K27me3;条件性敲除EZH2供者细胞证明EZH2为cGVHD/BO启动所必需;在硬化性cGVHD模型中JQ5减轻皮肤病变严重程度。
要点
- EZH2抑制剂JQ5和BET抑制剂JQ1各自改善cGVHD/BO小鼠肺功能并削弱生发中心反应。
- 条件性敲除EZH2供者细胞证明EZH2为cGVHD/BO启动所必需。
- 硬化性cGVHD模型中JQ5减轻皮肤病变严重程度。
核心结论
- 作者认为表观遗传靶向生发中心是治疗cGVHD的可行临床途径,EZH2抑制剂JQ5和BET溴结构域抑制剂JQ1在cGVHD/BO患者中展现EZH2i和BETi的临床潜力。
研究设计与样本
- 在具有闭塞性细支气管炎的临床相关小鼠cGVHD模型中测试抗癌染色质修饰酶抑制剂的疗效。
- 使用条件性EZH2敲除供者细胞验证EZH2在cGVHD/BO启动中的作用。
- 在硬化性cGVHD模型中测试JQ5对皮肤病变的影响。
- 分析接受JQ1或JQ5治疗的移植小鼠脾脏GCB细胞转录组。
主要发现
- EZH2抑制剂JQ5和BET溴结构域抑制剂JQ1各自改善肺功能并削弱生发中心反应。
- JQ5减少供者T细胞中EZH2介导的H3K27me3。
- 条件性EZH2敲除供者细胞证明EZH2为cGVHD/BO启动所必需。
- 硬化性cGVHD模型中JQ5减轻皮肤病变严重程度。
- cGVHD/BO GCB细胞中富集的多个炎症和信号通路被每种药物减少;JQ5治疗而非JQ1治疗的小鼠GCB细胞富集了也见于仅骨髓移植小鼠GCB细胞的促增殖通路。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in the field, chronic graft-versus-host-disease (cGVHD) remains a leading cause of morbidity and mortality following allogenic hematopoietic stem cell transplant. Because treatment options remain limited, we tested efficacy of anticancer, chromatin-modifying enzyme inhibitors in a clinically relevant murine model of cGVHD with bronchiolitis obliterans (BO). We observed that the novel enhancer of zeste homolog 2 (EZH2) inhibitor JQ5 and the BET-bromodomain inhibitor JQ1 each improved pulmonary function; impaired the germinal center (GC) reaction, a prerequisite in cGVHD/BO pathogenesis; and JQ5 reduced EZH2-mediated H3K27me3 in donor T cells. Using conditional EZH2 knockout donor cells, we demonstrated that EZH2 is obligatory for the initiation of cGVHD/BO. In a sclerodermatous cGVHD model, JQ5 reduced the severity of cutaneous lesions. To determine how the 2 drugs could lead to the same physiological improvements while targeting unique epigenetic processes, we analyzed the transcriptomes of splenic GCB cells (GCBs) from transplanted mice treated with either drug. Multiple inflammatory and signaling pathways enriched in cGVHD/BO GCBs were reduced by each drug. GCBs from JQ5- but not JQ1-treated mice were enriched for proproliferative pathways also seen in GCBs from bone marrow-only transplanted mice, likely reflecting their underlying biology in the unperturbed state. In conjunction with in vivo data, these insights led us to conclude that epigenetic targeting of the GC is a viable clinical approach for the treatment of cGVHD, and that the EZH2 inhibitor JQ5 and the BET-bromodomain inhibitor JQ1 demonstrated clinical potential for EZH2i and BETi in patients with cGVHD/BO.
引用
- Zaiken MC, Flynn R, Paz KG, et al. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022. PMID: 35226736. doi:10.1182/blood.2021014557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。